S

Saint Michael's Medical Center | Research Department

Research site
(Unclaimed)
Location
111 Central Avenue, Newark, New Jersey, United States of America

Site insights

Top conditions

Top treatments

Emtricitabine
Ritonavir
Tenofovir
Rilpivirine
Elvitegravir
Efavirenz
Tenofovir Disoproxil Fumarate
TAF
Maraviroc
TDF

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 57 total trials

A Clinical Trial of STP0404 in Treatment-Naïve Adults With HIV-1 Infection

The purpose of this study is to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of STP0404 in treatment naïve adult partici...

Enrolling
HIV-1-infection
Drug: Low-dose STP0404 (Pirmitegravir)
Drug: Placebo
Locations recently updated

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic di...

Enrolling
Human Immuno-deficiency Virus (HIV) Disease
Drug: Budigalimab
Drug: ABBV-382

This study will randomize patients recently discharged from the hospital with a confirmed diagnosis of type 1 acute myocardial infarction (Thygesen e...

Invitation-only
Acute Myocardial Infarction
Combination Product: Placebo
Combination Product: Selatogrel

The goal of this clinical study is to learn how safe and effective it is to switch to an oral therapy of Bictegravir/Emtricitabine/Tenofovir (B/F/TAF...

Enrolling
HIV-1-infection
Drug: B/F/TAF

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Enrolling
HIV-1-infection
Drug: Stable Baseline Regimen
Drug: Bictegravir

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose c...

Enrolling
HIV-1-infection
Drug: B/F/TAF
Drug: Placebo to match B/F/TAF

An open-label, pilot study of switching patients to Dovato who are currently taking Bitarvy who are virological suppressed (HIV-1 \< 50 copies/mL

Active, not recruiting
Human Immunodeficiency Virus
Drug: Dolutegravir/Lamivudine

Trial sponsors

Gilead Sciences logo
S
AbbVie logo
ViiV Healthcare logo
Abbott logo
Bristol-Myers Squibb (BMS) logo
J
L
National Cancer Institute (NCI) logo
Alexion Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems